Kornimate/medical-research-clean huggingface dataset:
carbon ion radiotherapy for atypical meningiomas

Conditions: Meningioma

Summary: treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. with this approach, local control ranges between 50 and 70%, depending on resection status. a series or smaller studies has shown that postoperative radiotherapy in this patient population can increase progression-free survival, which translates into increased overall survival. however, meningiomas are known to be radioresistant tumors, and radiation doses of 60 gy or higher have been shown to be necessary for tumor control. carbon ions offer physical and biological characteristics. due to their inverted dose profile and the high local dose deposition within the bragg peak precise dose application and sparing of normal tissue is possible. moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (rbe), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed. first data obtained within the phase i/ii trial performed at gsi in darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising. therefore, in the current phase ii-marcie-study a carbon ion boost will be applied to the macroscopic tumor (gross tumor volume, gtv) in conjunction with photon radiotherapy to the clinical target volume (ctv) in patients with atypical meningiomas after incomplete resection or biopsy. primary endpoint is progression-free survival rate, secondary endpoints are overall survival, safety and toxicity.


Eligibility criteria:
inclusion criteria: * histologically confirmed atypical meningioma * macroscopic tumor after biopsy or subtotal resection * simpson grade 4 or 5 * prior photon radiotherapy to the clinical target volume (ctv) of 48-52 gy * beginning of study treatment no later than 12 weeks after surgery * age ≥ 18 years of age * karnofsky performance score ≥ 60 * for women with childbearing potential, adequate contraception * ability of subject to understand character and individual consequences of the clinical trial * written informed consent (must be available before enrolment in the trial) exclusion criteria: * refusal of the patients to take part in the study * previous radiotherapy of the brain * optic nerve sheath meningioma (onsm) * time interval of \> 12 weeks after primary diagnosis (neurosurgical intervention) and beginning of study treatment * patients who have not yet recovered from acute toxicities of prior therapies * known carcinoma \< 5 years ago (excluding carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy * pregnant or lactating women * participation in another clinical study or observation period of competing trials, respectively

Keywords: atypical meningioma
a study to improve the fast ultrasound exam

Conditions: Hemoperitoneum

Summary: this research study aims to improve the standard exam called focused assessment with sonography in trauma (fast). the fast exam is an ultrasound test used to identify an abdominal bleed. the study will see if having patients roll on their right side improves the fast exam. making the fast exam better can help trauma doctors save the lives of patients with bleeding.


Eligibility criteria:
inclusion criteria: * all trauma patients who present as a trauma activation with clinical history or physical signs of blunt abdominal trauma. exclusion criteria: * pregnant females * prisoners * patients with prohibitive right sided chest trauma * patients in extremis undergoing salvage maneuvers (chest compressions or emergent surgical intervention) which prevents performance of an ultrasound examination * patient who leave against medical advice or are otherwise removed from the medical system before their work up has been completed
long-term efficacy and safety of hrs-7535 tablets in obese subjects

Conditions: Chronic Weight Management

Summary: the objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of hrs-7535 tablets inobesity.


Eligibility criteria:
inclusion criteria: 1. male or female subjects, 18-65 years of age at the time of signing informed consent; 2. subjects who have completed the entire 36-week treatment course of the hrs-7535-202 trial. 3. subjects who have a full understanding of the trial content, processes, and possible adverse reactions, and are capable and willing to comply with the protocol requirements to complete this study. exclusion criteria: 1. participants with poor compliance during the 36-week open-label extension treatment of the hrs-7535-202 trial; 2. pregnant, lactating, planning to conceive during the trial period, or fertile subjects unwilling to take effective contraceptive measures during the trial period. 3. any other conditions deemed unsuitable for participation in this clinical trial by the investigator.
tele-rehabilitation for female athletes with pelvic floor dysfunctions

Conditions: Pelvic Floor Disorders

Summary: pelvic floor dysfunctions (pfd) are especially prevalent among females. as conservative management, strengthening pelvic floor (pf) musculature under health supervision, regard an important research line. however, embarrassment of female athletes limits healthcare demands. new technologies could facilitate an autonomous but supervised tele-rehabilitation programs. this study will evaluate the effects of a 6-weeks strengthening pf program by using tele-rehabilitation, with or without intracavitary biofeedback, in the pf anatomo-functional characteristics, quality of life and sports performance of female athletes with pfd. to this end, 45 female athletes with self-reported pfd who train and compete in athletic in spain will be recruited and randomly distributed in three groups of the experimental study. during 6 weeks, all participants will use an specifically developed smartphone application (named actitud): the control group (cg) will have access to information about pf and direct communication with healthcare team; experimental group 1 (eg1) will have access to the same information and communication, and will perform a strengthening program for pf, which will be instructed by 3d avatars, while using an intracavitary biofeedback device that will inform about vaginal pressure; the experimental group 2 (eg2) will be similar to eg1, but they will not use the intracavitary biofeedback device. before and after these 6 weeks, anatomo-functional pf characteristics, quality of life, pfd symptoms and sports performance of all participants will be evaluated. as an additional outcome, the level of engagement of the athletes from experimental groups to complete the training program will be registered.

female athletes from eg1 and eg2 will complete the strengthening program for pf three times per week, during six weeks. each session will last about 20 minutes and exercises will be modified every two weeks to meet the principle of training progression and avoid athletes become bored.

Eligibility criteria:
inclusion criteria: * to train and compete in any of the track and field modalities * to have sports license from regional or national track and field federation in the season when study starts. * to have a self-reported pelvic floor disorder (urinary incontinence, fecal incontinence, sexual dysfunction or pelvic organ prolapse). exclusion criteria: * to have pelvic pain during the last three months. * to have recurrent infections of urinary tract during the last three months. * to be receiving physiotherapy treatment due to any pelvic floor disorder at the moment of the start of the study. * to have been pregnant during the year prior to the start of the study.

Keywords: female athletes track and field tele-rehabilitation strengthening
retrospective study to estimate the current status of patients with non-obstructive coronary artery disease

Conditions: Non-Obstructive Coronary Artery Disease

Summary: the study will estimate the current status of participants with non-obstructive coronary artery disease confirmed via coronary angiography.


Eligibility criteria:
inclusion criteria: * participants who had typical or atypical angina symptom before coronary angiography examination * underwent cag between 01 jan 2013 and 31 dec 2015 * other protocol defined inclusion criteria could apply exclusion criteria: * participant with history of percutaneous coronary intervention or coronary artery bypass surgery * participant with history of myocardial infarction * participant with history of cardiac transplant or valve surgery * presenting with acute myocardial infarction for coronary angiography * cag showed myocardial bridge and coronary stenosis greater than or equal to 50 percent during systole period * incomplete or missing data in cag report * other protocol defined exclusion criteria could apply

Keywords: non-obstructive coronary artery disease coronary angiography
impact of therapeutic strategies in the pediatric inflammatory bowel disease: a population based study (1988-2011).

Conditions: Pediatric Inflammatory Bowel Disease

Summary: crohn's disease (cd) and ulcerative colitis (uc) are chronic inflammatory bowel disease (ibd) and may affect all segments of the digestive tract.

crohn's disease (cd) and ulcerative colitis (uc) are chronic inflammatory bowel disease (ibd) and may affect all segments of the digestive tract. these are diseases of multifactorial origin in which environmental and genetic factors are predominant.the epimad registry, the world's largest epidemiological register for ibd, identifying all incident cases in the four departments of the north west of france showed between 1988 and 2007, an increase in the annual incidence of mc 71 % (6.5 / 105 (1988-1990) 11.1 / 105 (2006-2007) p \<0.0001) in the age group 10-19 years. at the same time, the annual incidence of uc decreased 4.3 / 3.5 105 inhabitants / 105 inhabitants (20%), with phenotypic presentation remained stable. the increase in the incidence of cd will contribute to increase its weight in the health system, particularly in the pediatric cd frequently associated with an aggressive phenotype causing specific complications such as malnutrition, pubertal delay or thrive. these complications have a important impact on the quality of life with a long-term risk of functional disability. they may be associated with increased mortality. immunosuppressants (azathioprine, methotrexate) have been used in pediatric forms only from the 90s and anti-tnf antibodies (infliximab and adalimumab), until the 2000s. these new therapeutic classes have profoundly changed the management of pediatric ibd. although there is little data on the impact of these new treatments, early introduction of immunosuppressive and anti-tnfs seems to influence the natural history of ibd diagnosed in pediatric age. anti-tnfs appear to be associated with more frequent and deeper remission. with the advent of these new treatment, new therapeutic targets such as endoscopic mucosal healing and more recently the deep remission combining clinical remission, biological and endoscopic, appears. however there is no data in the general population assessing the impact of new treatments and new therapeutic strategies in the pediatric population. potential risks associated with the increasing use and early use of biological treatments in this particular population remain to be determined in the general population. the main hypothesis of this study is that changes in therapeutic strategies in ibd diagnosed before 17 yeras old could influence the cumulative incidence of surgical resection and complications specific to this population as failure to thrive and delayed puberty, insertion socio-professional, the extension of the disease, hospitalization rates, and the rate of cancer.

Eligibility criteria:
inclusion criteria: patients in the pediatric cohort epimad registry with a diagnosis of cd or uc or probable between 1988 and 2011. exclusion criteria: * none

Keywords: crohn's disease (cd) pediatric inflammatory bowel disease
tdcs in people with subthreshold depression

Conditions: Subthreshold Depression

Summary: this study evaluates the effects of multi-session transcranial direct current stimulation on loneliness, mood and depressiveness in people with subthreshold depression.

depression-prone individuals will be invited and allocated to three groups, either the personalised transcranial direct current stimulation (tdcs) group, the conventional tdcs group, or the sham control group. after screening and at baseline prior to the tdcs sessions, participants will complete tests and questionnaires on depression symptoms, loneliness and mood, and they will also receive functional magnetic resonance imaging (mri) in a 3-tesla mri scanner. there will be a total of 10 sessions to be completed after the screening and baseline measures. for both personalised tdcs group and the conventional tdcs group, tdcs with 2 milliampere (ma) intensity will be delivered for 20 minutes in each session. for sham control group, the protocol will be similar, except that the stimulation only happens in the first 30 seconds in each session. especially for participants allocated to the personalised tdcs group, the stimulation site for each individual in this group may vary, depending on their brain activations and connectivity. the anodal stimulation sites for participants allocated to the conventional tdcs group and the sham control group will be f3 within the left dlpfc. immediately after and also 3-months after completing the 10 sessions, participants will be invited to complete again tests and questionnaires on depressive symptoms in addition to loneliness and mood, and they will also receive functional mri scanning in the 3t mri scanner. participants will also be prompted to self-report daily their loneliness and mood levels throughout the study.

Eligibility criteria:
inclusion criteria: * no histories of learning impairment, major psychiatric disorders including major depressive disorder or neurological disorders * at least primary school education * subthreshold depression exclusion criteria: * on medication or treatments within 2 weeks prior to the beginning of the study that would affect the individual's brain, cognitive and affective functions
efficacy of er: ysgg laser in treatment of peri-implantitis

Conditions: Peri-Implantitis

Summary: this study will be carried out to evaluate the efficacy of er: ysgg laser on oral biofilm removal from implant surface in various peri-implant defect morphology in the treatment of peri-implantitis as a primary objective. to assess the morphological changes and the biological response (biocompatibility) of implant surface after er: ysgg laser therapy through profilometer analysis and cell culture process to detect attachment, differentiation, and mineralization of isolated rat bone marrow mesenchymal stem cells (rbmmscs) respectively as secondary objectives.

this study will be carried out to evaluate the efficacy of er: ysgg laser on oral biofilm removal from implant surface in various peri-implant defect morphology in the treatment of peri-implantitis as a primary objective. to assess the morphological changes and the biological response (biocompatibility) of implant surface after er: ysgg laser therapy through profilometer analysis and cell culture process to detect attachment, differentiation, and mineralization of isolated rat bone marrow mesenchymal stem cells (rbmmscs) respectively as secondary objectives. the study was designed as an ex vivo study. four periodontally and systemically healthy volunteers of both gender are included in this study for the formation of in vivo plaque biofilm. each volunteer will wear a hard resin splint carrying six rough (machined implant; 3.3mm diameter, 8mm length) for 4 days to accumulate dental plaque naturally on the titanium surfaces of the implants. therefore, 24 implants will be assessed for er: ysgg laser therapy in different bone defect simulators.

Eligibility criteria:
inclusion criteria: * sex: female or male. * age: 25 - 55 years. * medically controlled according to medical coding of review of systems (ros) exclusion criteria: * tobacco smoking for at least 6 months before the study enrollment * participants with ill-fitting restorations in both upper first molars that affect the stability of the stent. * participants not following oral hygiene instructions. * participants on dental treatment during the study period. * participants with a history of drug administration * vulnerable group. * participants with long-term mouthwash administration.

Keywords: er: ysgg laser therapy peri-implantitis
modafinil in cancer related fatigue

Conditions: Cancer Related Fatigue; Quality of Life

Summary: cancer related fatigue (crf) is a highly prevalent and highly significant entity among patients with cancer. 'cancer related fatigue' is not a simple symptom, but is an entity in itself, in that it is different from routine fatigue. cancer related fatigue is that fatigue which persists even after rest and has significant effects on quality of life. the incidence of cancer related fatigue (crf) increases during radiation therapy (rt), with almost every patient on radiotherapy complaining of at-least some magnitude of fatigue. given that fatigue can affect treatment adherence by patients, it is important to initiate measures to either prevent or mitigate cancer related fatigue. the investigators intend to use modafinil in cancer related fatigue, in view of the fact that it has safety and efficacy in other diseases such as narcolepsy, multiple sclerosis and fibromyalgia. in addition, there have been a few small trials which have hinted towards benefit with the use of modafinil in cancer related fatigue. the investigators have chosen a dose of 100mg/day in the morning, to be compared with placebo. the study arm and the placebo arm will be stratified with respect to age, sex, disease site, baseline performance status. primary outcome would be fatigue, which will be assessed by the use of brief fatigue inventory (bfi). secondary outcomes include quality of life, improvements in performance status, changes in systolic and diastolic blood pressure, and changes in weight.


Eligibility criteria:
inclusion criteria: * patients with pathological confirmation of cancer * age 18 years to 70 years * performance status (karnofsky scale) not less than 60 * providing consent exclusion criteria: * psychiatric illness * hypertension * diabetes * thyroid disorders * epilepsy * tuberculosis

Keywords: cancer related fatigue quality of life modafinil radiation therapy radiotherapy
study to evaluate the safety and efficacy of abt-712 in subjects with moderate to severe chronic low back pain (clbp)

Conditions: Chronic Low Back Pain

Summary: the primary purpose of the study is to test the efficacy of 2 tablets (twice daily) of abt-712, compared to placebo, administered over a 4-week period in participants with moderate to severe mechanical chronic low back pain (clbp).

the study used a randomized withdrawal design with an open label (ol) period prior to a double-blind (db) period. participants who were receiving benefit and were tolerating abt-712 during the ol period were randomized into the db period. study drug was given for a total of 8 weeks, which included up to 3 weeks in ol, up to 4 weeks in db, and a 1-week db taper. during the ol period, all participants took increasing doses of abt-712 until they were taking 2 tablets, twice daily. during the db period, participants in the abt-712 group took 2 abt-712 tablets, twice daily throughout the 4 weeks, while participants in the placebo group took 2 placebo tablets twice daily.

Eligibility criteria:
inclusion criteria: * adult male and female subjects who voluntarily sign the informed consent * diagnosis of clbp of 6 months duration exclusion criteria: * incapacitated or bedridden subjects * subjects with history of surgical or invasive intervention

Keywords: effect on sleep interference by pain
automatic phenotyping of patients on 2d photography

Conditions: Dysmorphia; Orphan Diseases

Summary: the field of artificial intelligence is booming in medicine and in the field of diagnosis. the data can be varied: x-rays, pathology sections, or photographs. it is considered that 30 to 40% of the 7000 rare diseases described to date cause craniofacial dysmorphia. their detection sometimes requires the trained eye of a geneticist, because certain phenotypic traits are subtle. these diagnostic difficulties and the fact that certain diseases are extremely uncommon lead to considerable diagnostic delays


Eligibility criteria:
the patient inclusion criteria are: * patients followed in medical genetics, * patients undergoing maxillofacial surgery, or craniofacial surgery as part of the management of a pathology, of genetic origin or not, associated with dysmorphism of the head and neck, * patients for whom frontal and profile facial photographs are taken as part of their treatment. the inclusion criteria for control subjects are: * patients followed in maxillofacial surgery, for a disease other than a rare disease associated with dysmorphia in the head or neck: acute pathology (wound) or chronic (gynecomastia). * patients for whom frontal and profile facial photographs are taken as part of their treatment. the criteria for non-inclusion of patients are: * patients who have undergone facial or skull surgery before the first photo was taken. * person subject to a judicial safeguard measure. * people objecting to the reuse of their health data. the criteria for non-inclusion of control subjects are: * pathologies affecting facial symmetry (dental cellulitis, displaced fractures). * patient followed for dysmorphic syndrome or in whom dysmorphic syndrome has been suspected. * person subject to a judicial safeguard measure. * people objecting to the reuse of their health data.

Keywords: artificial intelligence
a study to compare the effects of sarpogrelate sustained release /aspirin combination therapy versus aspirin on blood viscosity in the patients with peripheral arterial disease and coronary artery disease

Conditions: Sarpogrelate; Blood Viscosity; Peripheral Arterial Disease; Coronary Artery Disease

Summary: this study is to compare the effects of sarpogrelate sustained release /aspirin combination therapy versus aspirin on blood viscosity in the patients with peripheral arterial disease and coronary artery disease


Eligibility criteria:
inclusion criteria: 1. both man and woman who is over 19 years old 2. identified as 10-75% of stenosis in coronary angiography or coronary cta(coronary computed tomography angiography) 3. patients who diagnosed with peripheral artery disease or has symptoms 4. written informed consent exclusion criteria: 1. patients who is scheduled surgery due to coronary artery disease or cerebral infarction disease. 2. patients who have taken aspirin within two weeks before randomization 3. patients who need antiplatelet or anticoagulant medication except aspirin 4. confirmed below results at screening * hemoglobin \<13g/dl * platelet \<60,000/µl * severe kidney disease patient with egfr(estimated glomerular filtration rate) \<30 ml/min/1.73 m2 (ckd-epi) 5. patients with a history of cerebrovascular and cardiovascular complications (brain infarction, transient cerebral ischemic seizures, myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary artery intervention) within the last six months 6. patients with bleeding 7. pregnant or lactating women 8. those participating in other clinical trials for investigational products 9. patients deemed to be ineligible to participate in the trial by investigator

Keywords: sarpogrelate sustained release